` LUCD (Lucid Diagnostics Inc) vs S&P 500 Comparison - Alpha Spread

L
LUCD
vs
S&P 500

Over the past 12 months, LUCD has outperformed S&P 500, delivering a return of +25% compared to the S&P 500's +13% growth.

Stocks Performance
LUCD vs S&P 500

Loading
LUCD
S&P 500
Add Stock

Performance Gap
LUCD vs S&P 500

Loading
LUCD
S&P 500
Difference
www.alphaspread.com

Performance By Year
LUCD vs S&P 500

Loading
LUCD
S&P 500
Add Stock

Competitors Performance
Lucid Diagnostics Inc vs Peers

Lucid Diagnostics Inc
Glance View

Market Cap
111.4m USD
Industry
Health Care

Lucid Diagnostics, Inc. develops medical testing devices. The company is headquartered in New York City, New York. The company went IPO on 2021-10-14. The firm is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or reflux, that leads to esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma (EAC). Its products include EsoCheck and EsoGuard. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in an office procedure. The company consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. EsoGuard is a bisulfite-converted next generation sequencing (NGS) deoxyribonucleic acid (DNA) assay performed on surface esophageal cells collected with EsoCheck. The firm is a subsidiary of PAVmed Inc.

LUCD Intrinsic Value
1.02 USD
Overvaluation 1%
Intrinsic Value
Price
L
Back to Top